



**Dr. Claudia Priglinger
(Funktionsoberärztin)**

Zur Person:

- seit 02/2010 Funktionsoberärztin an der Augenabteilung des AKH Linz
- 2008 - 2009 Assistenzärztin im Fach Augenheilkunde & Optometrie (AKH Linz)
- 2001 - 2007 Assistenzärztin im Fach Augenheilkunde & Optometrie (LMU München)
- 2001 - 2002 PostDoc am Department of Human Genetics and Protein Science, Helmholtz Center Neuherberg/München
- 2000 - 2001 Ärztin im Praktikum am Department für Dermatologie, Medizinische Fakultät der Universität Regensburg
- 1999 – 2000 Turnusärztin am AKH Linz
- 1998 – 1999 PostDoc Fellowship Wellman Laboratories of Photomedicine, Harvard Medical School, Boston
- 1998 Promotion zur Doktorin der gesamten Heilkunde
- 1991 – 1998 Studium der Humanmedizin an der Medizinischen Fakultät der Universität Wien
- 1990 – 1991 Studium der Architektur an der Technischen Universität Wien

Wissenschaftliche Publikationen:

1. **PUVA downregulates whn expression in primary mouse keratinocytes;** Alge C, Baxter RM, Doyle ME, Moor AC, Brissette JL, Ortel B. *J Photochem Photobiol B.* 2001 Nov 1;64:75-81.
2. **Retinal Pigment Epithelium Is Protected Against Apoptosis by alphaB-Crystallin.**Alge CS, Priglinger SG, Neubauer AS, Kampik A, Zillig M, Bloemendal H, Welge-Lussen U. *Invest Ophthalmol Vis Sci.* 2002 Nov;43(11):3575-82.
3. **Tissue Transglutaminase as a Modifying Enzyme of the Extracellular Matrix in PVR Membranes.**Priglinger SG, May CA, Neubauer AS, Alge CS, Schonfeld CL, Kampik A, Welge-Lussen U. *Invest Ophthalmol Vis Sci.* 2003 Jan;44(1):355-64.
4. **Optical coherence tomography for the detection of laser in situ keratomileusis in donor corneas.**Priglinger SG, Neubauer AS, May CA, Alge CS, Wolf AH, Mueller A, Ludwig K, Kampik A, Welge-Luessen U. *Cornea.* 2003 Jan;22(1):46-50.
5. **Comparative proteome analysis of native differentiated and cultured dedifferentiated human RPE cells.** Alge CS, Suppmann S, Priglinger SG, Neubauer AS, May CA, Hauck S, Welge-Lussen U, Ueffing M, Kampik A. *Invest Ophthalmol Vis Sci.* 2003 Aug;44(8):3629-41.
6. **Tele-screening for diabetic retinopathy with the retinal thickness analyzer.**Neubauer AS, Welge-Lussen UC, Thiel MJ, Alge C, Priglinger SG, Hirneiss C, Ulbig MW, Kampik A. *Diabetes Care.* 2003 Oct;26:2890-7.
7. **Laser in situ keratomileusis in human corneas; New organ culture model.** May CA, Priglinger SG, Neubauer AS, Alge CS, Ludwig K, Kampik A, Welge-Lüßen U. *J Cataract Refract Surg.* 2004 Jan;30(1):186-93.
8. **TGF-beta2-Induced Cell Surface Tissue Transglutaminase Increases Adhesion and Migration of RPE Cells on Fibronectin through the Gelatin-Binding Domain.** Priglinger SG, Alge CS, Neubauer AS, Kristin N, Hirneiss C, Eibl K, Kampik A, Welge-Lussen U. *Invest Ophthalmol Vis Sci.* 2004 Mar;45(3):955-63.
9. **Functional outcome after trypan-blue-assisted vitrectomy for macular pucker: a prospective, randomized, comparative trial.**Haritoglou C, Eibl K, Schaumberger M, Müller AJ, Priglinger S, Alge C, Kampik A. *Am J Ophthalmol* 2004; 138: 1-5
10. **Pulsed Electron Avalanche Knife (PEAK-fc) in vitreoretinal surgery** Priglinger SG, Haritoglou C, Mueller A, Grueterich M, Strauss RW, Alge CS, Gandorfer A, Palanker D, Kampik A.: *Retina.* 2005;25:889-896
11. **Pulsed Electron Avalanche Knife (PEAK-fc®) for Dissection of Retinal Tissue.** Priglinger SG, Haritoglou C, Palanker DV, Alge CS, Gandorfer A, Kampik A. *Arch Ophthalmol.* 2005 Oct;123(10):1412-8.
12. **An evaluation of novel dyes for intraocular surgery** Haritoglou C, Yu A, Freyer W, Priglinger SG, May CA, Alge C, Eibl K, Welge-Luessen U, Kampik A.. *Invest Ophthalmol Vis Sci.* 2005;46:3315-3322.
13. **Absence of scar formation in a human donor cornea with prior laser in situ keratomileusis (LASIK)**Priglinger SG, May CA, Alge CS, Wolf A, Neubauer AS, Kampik A, Welge-Lüßen U *J Cataract Refract Surg.* 2005;31:1403-1408.

14. **Mapping of retinal pigment epithelium in exudative age related macular degeneration.** Neubauer AS, Thiel M, Priglinger S, Chryssafis C, Alge C, Welge-Lüssen U, Kampik A. *Graefes Arch Clin Exp Ophthalmol.* 2005;18:1-10
15. **Galectin-1 influences migration of retinal pigment epithelial cells.** Alge CS, Priglinger SG, Kook D, Haritoglou C, Welge-Luessen U, Kampik A. *Invest Ophthalmol Vis Sci.* 2006; 47:415-426.
16. **Immunohistochemical findings after LASIK confirm in vitro LASIK model;** Priglinger SG, May CA, Alge CS, Wolf A, Neubauer AS, Haritoglou C, Kampik A, Welge-Lüssen U. *Cornea.* 2006; 25:331-335.
17. **Differential protein profiling of primary versus immortalized human RPE cells identifies expression patterns associated with cell-matrix interactions and cell survival.** Alge CS, Hauck SM, Priglinger SG, Kampik A, Ueffing M. *J Proteome Res.* 2006; 5:862-878.
18. **Tissue Transglutaminase modifies Extracellular Matrix after Glaucoma Filtering Surgery** Priglinger SG*, Alge CS*, Kook D, Thiel M, Schumann R, Kampik A, Welge-Luessen U. *Invest Ophthalmol Vis Sci.* 2006;47:3835-45. (* contributed equally)
19. **Pulsed Electron Avalanche Knife (PEAK-fc): New Technology for capsulotomy in congenital and mature cataract.** Priglinger SG, Haritoglou C, Palanker D, Kook D, Grueterich M, Mueller A, Alge CS, Kampik A. *J Cataract Refract Surg.* 2006;32:1085-1088.
20. **Keratinocyte transglutaminase in proliferative vitreoretinopathy.** Priglinger SG, Alge CS, Kreutzer TC, Neubauer AS, Haritoglou C, Kampik A, Welge-Luessen U. *Invest Ophthalmol Vis Sci.* 2006; *Invest Ophthalmol Vis Sci.* 2006;47:4990-7.
21. **Pulsed Electron Avalanche Knife (PEAK-fc): New Technology for Cataract Surgery.** Priglinger SG, Palanker D, Alge CS, Kreutzer TC, Haritoglou C, Grueterich M, Kampik A. *Br J Ophthalmol.* 2007; 91:949-54.
22. **Intravitreal Bevacizumab for Central Retinal Vein Occlusion Six Month Results of a Prospective Trial.** Priglinger S, Wolf. A, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A. *Retina.* 2007; 27:1004-12.
23. **Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.** Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A. *Br. J Ophthalmol.* 2008; 92:351-5.
24. **Capsular tension ring-based in vitro capsule opacification model.** Burger J, Kreutzer T, Alge CS, Strauss RW, Eibl K, Haritoglou C, Neubauer AS, Kampik A, Priglinger SG. *J Cataract Refract Surg.* 2008;23:1167-72.
25. **Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax and Bcl-2 expression.** Kernt M, Neubauer AS, Liegl R, Eibl KH, Alge CS, Lackerbauer CA, Ulbig MW, Kampik A. *J Cataract Refract Surg.* 2009; 35:354-62.
26. **Intracameral Moxifloxacin: In Vitro Safety on Human Ocular Cells.** Kernt M, Neubauer AS, Liegl RG, Lackerbauer CA, Eibl KH, Alge CS, Ulbig MW, Kampik A. *Cornea.* 2009 Jun;28:553-61.
27. **Oxidative Stress-mediated Induction of MMP-1 and MMP-3 in Human RPE Cells.** Alge-Priglinger CS, Kreutzer T, Obholzer K, Wolf A, Mempel M, Kampik A, Priglinger SG. *Invest Ophthalmol Vis Sci.* 2009;50:5495-5503.

28. **Inhibition of Human Retinal Pigment Epithelial Cell Attachment, Spreading, and Migration by the Human Lectin Galectin-1.** Alge-Priglinger CS, André S, Kreutzer TC, Deeg C, Kampik A, Schöfl H, Priglinger SG, Gabius HJ *Mol Vis. Mol Vis.* 2009;15:2162-2173.
29. **ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations.** Kortvely E, Hauck SM, Duetsch G, Gloeckner CJ, Kremmer E, Alge-Priglinger CS, Deeg C, Ueffing M. *Invest Ophthalmol Vis Sci.* 2009 Aug 20. [Epub ahead of print]